252 related articles for article (PubMed ID: 35696531)
1. Combined treatment with anti-PSMA CAR NK-92 cell and anti-PD-L1 monoclonal antibody enhances the antitumour efficacy against castration-resistant prostate cancer.
Wang F; Wu L; Yin L; Shi H; Gu Y; Xing N
Clin Transl Med; 2022 Jun; 12(6):e901. PubMed ID: 35696531
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
4. A Crosstalk Between Castration-Resistant Prostate Cancer Cells, M2 Macrophages, and NK Cells: Role of the ATM-PI3K/AKT-PD-L1 Pathway.
Jin H; Zhu J; Xuan R; Zhou Y; Xue B; Yang D; Gao J; Zang Y; Xu L
Immunol Invest; 2023 Nov; 52(8):941-965. PubMed ID: 37732622
[TBL] [Abstract][Full Text] [Related]
5. Adipocytes affect castration-resistant prostate cancer cells to develop the resistance to cytotoxic action of NK cells with alterations of PD-L1/NKG2D ligand levels in tumor cells.
Xu L; Shen M; Chen X; Zhu R; Yang DR; Tsai Y; Keng PC; Chen Y; Lee SO
Prostate; 2018 Apr; 78(5):353-364. PubMed ID: 29330929
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells.
Lee MY; Robbins Y; Sievers C; Friedman J; Abdul Sater H; Clavijo PE; Judd N; Tsong E; Silvin C; Soon-Shiong P; Padget MR; Schlom J; Hodge J; Hinrichs C; Allen C
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741731
[TBL] [Abstract][Full Text] [Related]
7. The establishment of polypeptide PSMA-targeted chimeric antigen receptor-engineered natural killer cells for castration-resistant prostate cancer and the induction of ferroptosis-related cell death.
Wu L; Liu F; Yin L; Wang F; Shi H; Zhao Q; Yang F; Chen D; Dong X; Gu Y; Xing N
Cancer Commun (Lond); 2022 Aug; 42(8):768-783. PubMed ID: 35706368
[TBL] [Abstract][Full Text] [Related]
8. The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.
Dong W; Wu X; Ma S; Wang Y; Nalin AP; Zhu Z; Zhang J; Benson DM; He K; Caligiuri MA; Yu J
Cancer Discov; 2019 Oct; 9(10):1422-1437. PubMed ID: 31340937
[TBL] [Abstract][Full Text] [Related]
9. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
Yuan X; Sun Z; Yuan Q; Hou W; Liang Q; Wang Y; Mo W; Wang H; Yu M
Invest New Drugs; 2021 Feb; 39(1):34-51. PubMed ID: 32772342
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effects of NK cells and anti-PD-L1 antibody with antibody-dependent cellular cytotoxicity in PD-L1-positive cancer cell lines.
Park JE; Kim SE; Keam B; Park HR; Kim S; Kim M; Kim TM; Doh J; Kim DW; Heo DS
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32830112
[TBL] [Abstract][Full Text] [Related]
11. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
[TBL] [Abstract][Full Text] [Related]
12. Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer.
Montagner IM; Penna A; Fracasso G; Carpanese D; Dalla Pietà A; Barbieri V; Zuccolotto G; Rosato A
Cells; 2020 Jun; 9(6):. PubMed ID: 32498368
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
Tang M; Gao S; Zhang L; Liu B; Li J; Wang Z; Zhang W
Prostate; 2020 Jul; 80(10):742-752. PubMed ID: 32449811
[TBL] [Abstract][Full Text] [Related]
14. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.
Boyerinas B; Jochems C; Fantini M; Heery CR; Gulley JL; Tsang KY; Schlom J
Cancer Immunol Res; 2015 Oct; 3(10):1148-1157. PubMed ID: 26014098
[TBL] [Abstract][Full Text] [Related]
16. TIGIT immune checkpoint blockade enhances immunity of human peripheral blood NK cells against castration-resistant prostate cancer.
Wang F; Liu S; Liu F; Xu T; Ma J; Liang J; Wang J; Liu D; Yang F; Li J; Xing N
Cancer Lett; 2023 Aug; 568():216300. PubMed ID: 37414394
[TBL] [Abstract][Full Text] [Related]
17. Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells.
Robbins Y; Greene S; Friedman J; Clavijo PE; Van Waes C; Fabian KP; Padget MR; Abdul Sater H; Lee JH; Soon-Shiong P; Gulley J; Schlom J; Hodge JW; Allen CT
Elife; 2020 Jul; 9():. PubMed ID: 32633234
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
Supimon K; Sangsuwannukul T; Sujjitjoon J; Chieochansin T; Junking M; Yenchitsomanus PT
Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers.
Ba H; Dai Z; Zhang Z; Zhang P; Yin B; Wang J; Li Z; Zhou X
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720496
[TBL] [Abstract][Full Text] [Related]
20. Prostate cancer cells synergistically defend against CD8
Li D; Zhou X; Xu W; Chen Y; Mu C; Zhao X; Yang T; Wang G; Wei L; Ma B
Cancer Med; 2023 Aug; 12(15):16405-16415. PubMed ID: 37501397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
